文献速递血液透析通路

体重指数对血液透析自体动静脉内瘘结局的影响

Impact of Body Mass Index on Outcomes of Autogenous Fistulas for Hemodialysis Access.
PubMed 文献 · Ann Vasc Surg · 2020-04-25

该回顾性队列研究纳入2007至2014年美国肾脏数据系统中300778例新发血透患者,按BMI分层评估自体动静脉内瘘的成熟、干预、通畅率与死亡。结果显示仅III度肥胖患者内瘘成熟率降低6%,BMI两端者通畅率较低,但BMI越高患者生存越好。

要点

  • III度肥胖与自体动静脉内瘘成熟率降低独立相关。
  • 体重过低与III度肥胖均与一期、一期辅助及二期通畅率降低相关。
  • BMI升高与患者生存改善相关,但需权衡内瘘成熟风险。

核心结论

  • 严重肥胖与自体动静脉内瘘成熟率下降相关,BMI两端与通畅率降低相关,但较高BMI与更好的患者生存相关。

研究设计与样本

  • 回顾性研究纳入美国肾脏数据系统中2007至2014年间启动血透的300778例患者,按BMI分为体重过低、正常、超重、I至III度肥胖。

主要发现

  • III度肥胖患者内瘘成熟率较正常体重者降低6%(aHR 0.94,95%CI 0.89-0.99,P=0.02),其余BMI组成熟率无显著差异。
  • 体重过低者一期(aHR 0.93,95%CI 0.91-0.96,P<0.001)、一期辅助(aHR 0.90,95%CI 0.88-0.93,P<0.001)及二期通畅率(aHR 0.89,95%CI 0.86-0.92,P<0.001)均低于正常体重者。
  • III度肥胖者一期(aHR 0.92,95%CI 0.90-0.93,P<0.001)、一期辅助(aHR 0.90,95%CI 0.88-0.92,P<0.001)及二期通畅率(aHR 0.93,95%CI 0.91-0.94,P<0.001)分别降低8%、10%和7%。
  • 患者生存率随BMI升高而改善。

临床怎么用

  • 对接近终末期肾病的III度肥胖患者,可考虑提前转诊行动静脉内瘘放置,以留出成熟时间供首次透析使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of obesity is increasing in the United States. The treatment of end-stage renal disease (ESRD) via hemodialysis spans the spectrum of body mass index (BMI). This study examines the impact of BMI on outcomes of autogenous fistulas for hemodialysis access in a large population-based cohort of patients. METHODS: A retrospective study of all patients in the prospectively maintained United States Renal Database System who initiated hemodialysis between 2007 and 2014 was performed. Chi-squared test, t-tests, Kaplan-Meier estimates, log-rank tests, multivariable logistic and Cox regression analysis were employed to evaluate access maturation, interventions, patency, and mortality. RESULTS: There were 300,778 patients studied. Of these, 9,394 (3.1%) were underweight, 87,351 (29.1%) were normal weight, 86,101 (28.6%) were overweight, 57,047 (19%) were obese class I, 31,077 (10.3%) were obese class II, and 29,808 (9.9%) were obese class III. There was no significant difference in maturation for patients who were underweight (adjusted hazard ratio [aHR] 0.97, 95% CI 0.89-1.06, P = 0.48), overweight (aHR 1.01, 95% CI 0.97-1.05, P = 0.66), obese class I (aHR 1.05, 95% CI 0.99-1.09, P = 0.22), or obese class II (aHR 1.01, 95% CI 0.94-1.05, P = 0.98 relative to normal weight. However, there was a 6% decrease in maturation for obese class III patients (aHR 0.94, 95% CI 0.89-0.99, P = 0.02) compared to normal weight patients. Primary (aHR 0.93, 95% CI 0.91-0.96, P < 0.001), primary assisted (aHR 0.90, 95% CI 0.88-0.93, P < 0.001), and secondary patency (aHR 0.89, 95% CI 0.86-0.92, P < 0.001) were lower for underweight compared to normal weight patients. There was 8%, 10%, and 7% decrease in primary (aHR 0.92, 95% CI 0.90-0.93, P < 0.001), primary assisted (aHR 0.90, 95% CI 0.88-0.92, P < 0.001), and secondary patency (aHR 0.93, 95% CI 0.91-0.94, P < 0.001) respectively for patients in obese class III compared to patients with normal weight. There was an increase in patient survival with increasing BMI. CONCLUSIONS: In this population-based cohort of hemodialysis-dependent patients, severe obesity was associated with a decrease in fistula maturation. Extremes of BMI were associated with lower patency, but higher BMI was associated with better patient survival. Obese patients nearing ESRD might require earlier referral for arteriovenous fistula (AVF) placement in order to allow for maturation and AVF use at incident hemodialysis.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Arhuidese IJ, Holscher CM, Elemuo C, et al. Impact of Body Mass Index on Outcomes of Autogenous Fistulas for Hemodialysis Access. Ann Vasc Surg. 2020. PMID: 32339695. doi:10.1016/j.avsg.2020.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。